A
Alimera Sciences
Develops and commercializes prescription ophthalmic pharmaceuticals
At a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Alpharetta, United States
- Listing
- IPO 2010
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- DADomain Associates
- SPScale Venture Partners
- IPIntersouth Partners
Polaris Partners
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Alumni founders
Former Alimera Sciences employees who went on to found companies, sorted by Dealroom signal score.
Andreas MuehlerUnited States
CTClean Crop TechnologiesEst. 2019
Jean GARRECFranceGlobal footprint
team presence
across markets
Patents
3 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alimera Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alimera Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.